📝 Amerise Biosciences Ltd — results explained
Quarter ended March 2026 (Q4 FY26)
Amerise Biosciences Ltd reported revenue of ₹0 crore for the quarter ended March 2026 (Q4 FY26), down 57.9% from ₹0 crore in the same quarter last year, and up 100.0% sequentially over the December 2025 quarter.
Net profit fell 45.5% year-on-year to ₹0 crore, from ₹0 crore. Earnings per share (EPS) came in at ₹0.01.
Operating profit stood at ₹0 crore — an operating margin (OPM) of 75.0%, compared with 57.9% in the year-ago quarter.
Full year and trailing twelve months
For the full year FY26, Amerise Biosciences Ltd posted revenue of ₹0 crore, a growth of 31.6% over FY25, with a net profit of ₹0 crore (up 100.0% year-on-year).
On a trailing-twelve-month (TTM) basis, revenue stands at ₹0 crore with a net profit of ₹0 crore.
Valuation snapshot
At the current price of ₹0.77, 531681 has a market capitalisation of ₹6 crore and a trailing P/E of about 277.5.
Within the Plastic Products - Industrial industry, it is the 25th-largest of the 36 companies we track by market value.
Shareholding pattern
As of Jun 2026, public shareholders 100.00% of Amerise Biosciences Ltd.